Publication:
Larynx angioedema as a signal in chronic lymphocytic leukemia: a case based guide for acquired angioedema in the setting of lymphoproliferative disorders

dc.contributor.coauthorÖztürk, Erman
dc.contributor.kuauthorÖztürk, Ayşe Bilge
dc.contributor.kuauthorKısakürek, Zeynep Büşra
dc.contributor.kuauthorSönmez, Sadi Can
dc.contributor.kuauthorOsmanbaşoğlu, Emre
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unitKoç University Hospital
dc.contributor.yokid147629
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T12:40:58Z
dc.date.issued2021
dc.description.abstractPatients with angioedema can present to the internal medicine, emergency medicine, dermatology, or ear nose throat clinics. Physicians may need to assess the patients whose angioedema is unresponsive to antihistamines systematically in collaboration with other subspecialties including hematology, rheumatology, allergy, and immunology. We aimed to provide a concise review of the diagnosis and multi-disciplinary management of acquired angioedema through a case presentation. A 61-year-old woman presented with recurrent angioedema of 4 episodes within one year. She was evaluated by various disciplines such as dermatology and emergency medicine. Antihistamines and steroids were not effective. The complete blood count (CBC) results indicated lymphocytosis (lymphocyte count=9100 k/mu L) and further evaluation of the lymphocytosis with flow cytometry immunophenotyping confirmed a diagnosis of chronic lymphocytic leukemia. Since the acquired angioedema diagnosis was confirmed with low C4, C1q, and C1 esterase inhibitor levels, Rituximab 375 mg/m(2) was administered once a week for 4 weeks. The frequency of attacks decreased after rituximab therapy and none of them were life-threatening. In conclusion, when the effective treatment is initiated for the primary diagnosis in acquired angioedema, the numerous emergency department visits, hospitalizations, and the mortality due to life-threatening angioedema episodes can be avoided.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.issue2
dc.description.openaccessYES
dc.description.publisherscopeNational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume19
dc.formatpdf
dc.identifier.doi10.21911/aai.614
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03198
dc.identifier.issn1308-9234
dc.identifier.linkhttps://doi.org/10.21911/aai.614
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85153887333
dc.identifier.urihttps://hdl.handle.net/20.500.14288/2222
dc.identifier.wos687772900009
dc.keywordsAngioedema
dc.keywordsLarynx angioedema
dc.keywordsEmergency
dc.keywordsChronic lymphocytic leukemia
dc.keywordsLife-threatening angioedema
dc.languageEnglish
dc.publisherBuluş Design
dc.relation.grantnoNA
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/9960
dc.sourceAsthma Allergy Immunology / Astım Allerji İmmünoloji
dc.subjectAllergy
dc.titleLarynx angioedema as a signal in chronic lymphocytic leukemia: a case based guide for acquired angioedema in the setting of lymphoproliferative disorders
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0003-0166-424X
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.kuauthorÖztürk, Ayşe Bilge
local.contributor.kuauthorKısakürek, Zeynep Büşra
local.contributor.kuauthorSönmez, Sadi Can
local.contributor.kuauthorOsmanbaşoğlu, Emre

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
9960.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format